{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:06:24Z","timestamp":1793271984974,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Vaginal estrogen for genitourinary syndrome of menopause (GSM) should be used with caution in women with contraindications, highlighting the need for effective treatment alternatives.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the severity of GSM after vaginal laser vs estrogen therapy.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n The PubMed, Embase, and Cochrane Library databases were searched for articles published from database inception to April 8, 2022, with no language restrictions. Reference lists were also searched.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Randomized clinical trials (RCTs) that compared the use of lasers with vaginal estrogen in adults were selected.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Two investigators independently extracted data from included studies. The Cochrane risk of bias tool for RCTs was used to assess risk of bias of each study. A random-effects model was used to pool mean differences (MDs) with 95% CIs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were Vaginal Analog Scale (VAS; higher scores indicate severer symptoms), Vaginal Health Index (VHI; higher scores indicate better vaginal health), Vaginal Maturation Index (VMI; higher scores indicate higher estrogen effect on the vaginal epithelium), Female Sexual Function Index (FSFI; higher scores indicate better female sexual function), and Sexual Quotient\u2013Female (SQ-F; higher scores indicate better female sexual function) questionnaire scores. Urinary symptoms were assessed as an additional outcome. Data analyses were performed from April 9 to 12, 2022.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 6 RCTs with 270 women with GSM were included (135 were randomized to laser therapy and 135 to estrogen therapy; mean age ranged from 54.6 to 61.0 years). No significant differences were found between carbon dioxide laser and vaginal estrogen from baseline to the end of follow-up in overall VAS scores (MD, \u22120.16; 95% CI, \u22120.67 to 0.36;\n \n I\n 2<\/jats:sup>\n <\/jats:italic>\n , 33.31%), VHI (MD, 0.20; 95% CI, \u22120.56 to 0.97;\n \n I\n 2<\/jats:sup>\n <\/jats:italic>\n , 83.25%), VMI (MD, \u22120.56; 95% CI, \u22121.14 to 0.02;\n \n I\n 2<\/jats:sup>\n <\/jats:italic>\n , 35.07%), FSFI (MD, \u22120.04; 95% CI, \u22120.45 to 0.36;\n \n I\n 2<\/jats:sup>\n <\/jats:italic>\n , 41.60%), and SQ-F (\n P<\/jats:italic>\n \u2009=\u2009.37 based on 1 study). Other questionnaire-based outcome measures demonstrated no difference between groups from baseline to the end of follow-up for changes in urinary symptoms.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This systematic review and meta-analysis of RCTs found that vaginal laser treatment is associated with similar improvement in genitourinary symptoms as vaginal estrogen therapy. Further research is needed to test whether vaginal laser therapy could be a potential treatment option for women with contraindications to vaginal estrogen.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.32563","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T11:03:59Z","timestamp":1663758239000},"page":"e2232563","source":"Crossref","is-referenced-by-count":29,"title":["Comparison of Severity of Genitourinary Syndrome of Menopause Symptoms After Carbon Dioxide Laser vs Vaginal Estrogen Therapy"],"prefix":"10.1001","volume":"5","author":[{"given":"Yeu-Chai","family":"Jang","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Wan Fang Hospital, Taipei Medical University, Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Yan","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsi-Lan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"issue":"6","key":"zoi220925r1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/GME.0000000000001752","article-title":"Genitourinary syndrome of menopause: a systematic review on prevalence and treatment.","volume":"28","author":"Mili","year":"2021","journal-title":"Menopause"},{"issue":"9","key":"zoi220925r2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society.","volume":"27","author":"Faubion","year":"2020","journal-title":"Menopause"},{"issue":"5","key":"zoi220925r3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/GME.0000000000001260","article-title":"The burden of vulvovaginal atrophy on women\u2019s daily living: implications on quality of life from a face-to-face real-life survey.","volume":"26","author":"Nappi","year":"2019","journal-title":"Menopause"},{"issue":"4","key":"zoi220925r4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/GME.0000000000001275","article-title":"Women\u2019s experience of vulvovaginal symptoms associated with menopause.","volume":"26","author":"Shifren","year":"2019","journal-title":"Menopause"},{"issue":"8","key":"zoi220925r5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001500.pub3","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women.","volume":"2016","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"zoi220925r6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.maturitas.2012.11.012","article-title":"Effective treatment of vaginal atrophy with isoflavone vaginal gel.","volume":"74","author":"Lima","year":"2013","journal-title":"Maturitas"},{"issue":"7","key":"zoi220925r7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/GME.0000000000001797","article-title":"Comparison of topical fractional CO2 laser and vaginal estrogen for the treatment of genitourinary syndrome in postmenopausal women: a randomized controlled trial.","volume":"28","author":"Dutra","year":"2021","journal-title":"Menopause"},{"issue":"4","key":"zoi220925r8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1089\/jwh.2007.0407","article-title":"A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice.","volume":"17","author":"Shulman","year":"2008","journal-title":"J Womens Health (Larchmt)"},{"issue":"1","key":"zoi220925r9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/GME.0000000000001416","article-title":"A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET trial.","volume":"27","author":"Paraiso","year":"2020","journal-title":"Menopause"},{"issue":"11","key":"zoi220925r11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1097\/GME.0000000000001845","article-title":"Vaginal CO2 laser therapy versus sham for genitourinary syndrome of menopause management: a systematic review and meta-analysis of randomized controlled trials.","volume":"28","author":"Khamis","year":"2021","journal-title":"Menopause"},{"issue":"3","key":"zoi220925r12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jmig.2020.08.001","article-title":"The efficacy of vaginal laser and other energy-based treatments on genital symptoms in postmenopausal women: a systematic review and meta-analysis.","volume":"28","author":"Li","year":"2021","journal-title":"J Minim Invasive Gynecol"},{"issue":"3","key":"zoi220925r13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.34172\/jlms.2020.49","article-title":"The effect of the CO2 fractional laser or premarin vaginal cream on improving sexual function in menopausal women: a randomized controlled trial.","volume":"11","author":"Eftekhar","year":"2020","journal-title":"J Lasers Med Sci"},{"issue":"8","key":"zoi220925r14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/lsm.v52.8","article-title":"Efficacy of fractional CO2 laser, promestriene, and vaginal lubricant in the treatment of urinary symptoms in postmenopausal women: a randomized clinical trial.","volume":"52","author":"Aguiar","year":"2020","journal-title":"Lasers Surg Med"},{"key":"zoi220925r15","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"zoi220925r16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ajog.2004.04.047","article-title":"The use of Visual Analog Scale in urogynecologic research: a psychometric evaluation.","volume":"191","author":"Lukacz","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"zoi220925r17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/GME.0000000000000955","article-title":"Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.","volume":"25","author":"Cruz","year":"2018","journal-title":"Menopause"},{"issue":"1","key":"zoi220925r18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00192-014-2464-0","article-title":"Assessment of vaginal atrophy: a review.","volume":"26","author":"Weber","year":"2015","journal-title":"Int Urogynecol J"},{"issue":"3","key":"zoi220925r19","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/j.fertnstert.2009.07.1173","article-title":"The female sexual function index (FSFI): a potential \u201cgold standard\u201d measure for assessing therapeutically-induced change in female sexual function.","volume":"92","author":"Sand","year":"2009","journal-title":"Fertil Steril"},{"issue":"1","key":"zoi220925r20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12905-018-0693-y","article-title":"Consistency of three different questionnaires for evaluating sexual function in healthy young women.","volume":"18","author":"da Costa","year":"2018","journal-title":"BMC Womens Health"},{"issue":"2","key":"zoi220925r21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/(ISSN)1520-6777","article-title":"Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory.","volume":"14","author":"Uebersax","year":"1995","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"zoi220925r22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12955-021-01721-z","article-title":"Identification of the Urogenital Distress Inventory-6 and the Incontinence Impact Questionnaire-7 cutoff scores in urinary incontinent women.","volume":"19","author":"Skorupska","year":"2021","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"zoi220925r24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/M13-2886","article-title":"Random-effects meta-analysis of inconsistent effects: a time for change.","volume":"160","author":"Cornell","year":"2014","journal-title":"Ann Intern Med"},{"key":"zoi220925r25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method.","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"zoi220925r27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/GME.0000000000001333","article-title":"Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial.","volume":"26","author":"Politano","year":"2019","journal-title":"Menopause"},{"issue":"3","key":"zoi220925r28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jsxm.2017.01.010","article-title":"The women\u2019s EMPOWER survey: identifying women\u2019s perceptions on vulvar and vaginal atrophy and its treatment.","volume":"14","author":"Kingsberg","year":"2017","journal-title":"J Sex Med"},{"issue":"3","key":"zoi220925r29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jsxm.2017.01.011","article-title":"The women\u2019s EMPOWER survey: women\u2019s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate.","volume":"14","author":"Krychman","year":"2017","journal-title":"J Sex Med"},{"issue":"7","key":"zoi220925r30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/GME.0000000000001315","article-title":"Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review.","volume":"26","author":"Constantine","year":"2019","journal-title":"Menopause"},{"issue":"1","key":"zoi220925r31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women\u2019s Health Initiative Observational Study.","volume":"25","author":"Crandall","year":"2018","journal-title":"Menopause"},{"issue":"2","key":"zoi220925r32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ijgo.v158.2","article-title":"Efficacy of CO2 laser treatment in postmenopausal women with vulvovaginal atrophy: a meta-analysis.","volume":"158","author":"Liu","year":"2022","journal-title":"Int J Gynaecol Obstet"},{"key":"zoi220925r33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.maturitas.2017.07.007","article-title":"CO2-laser for the genitourinary syndrome of menopause. How many laser sessions?","volume":"104","author":"Athanasiou","year":"2017","journal-title":"Maturitas"},{"key":"zoi220925r26","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins","year":"2011"},{"key":"zoi220925r10","unstructured":"US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, MD, on efforts to safeguard women\u2019s health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for \u201cvaginal rejuvenation.\u201d Accessed April 15, 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims"},{"key":"zoi220925r23","unstructured":"Bristol Urological Institute. The International Consultation on Incontinence Questionnaire 2014\u20132022. Accessed April 9, 2022. https:\/\/iciq.net"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2796567\/jang_2022_oi_220925_1663173114.55751.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T11:04:07Z","timestamp":1663758247000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796567"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.32563","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]}}}